This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Komlossy Law, P.A. Announces Investigation Of Mako Surgical Corp.

Komlossy Law, P.A., a Florida-based firm, is investigating the Board of Directors of Mako Surgical Corp. (“Mako” or the “Company”) (NASDAQ:MAKO) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to complete a sale of the Company to Stryker Corp. ("Stryker") in a transaction valued at approximately $1.65 billion. Pursuant to the terms of the proposed transaction, Mako shareholders are to receive $30.00 for each share of the Company.

The investigation involves whether the Board of Directors of Mako breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the transaction, and whether the transaction is fair to shareholders with respect to price, process and disclosure of all material information.

If you own Mako stock and wish to obtain additional information about your rights as a shareholder, or if you have information about the above investigation, please contact Emily C. Komlossy, Esq. via email at or by telephone toll free at (855) 858-1233.

Komlossy Law, P.A. represents shareholders in complex litigation, including class action and derivative litigation. Komlossy Law, P.A. may co-counsel with another firm, or refer a case to another firm. More information is available through the firm’s website,, and upon request. Emily C. Komlossy is the attorney responsible for the content of this release.
Emily C. Komlossy, Esq.
Komlossy Law, P.A.
2131 Hollywood Boulevard, Suite 408
Hollywood, FL 33020

Attorney Advertisement. Past results do not guarantee or predict a similar outcome with respect to any future matter.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,802.62 +26.19 0.16%
S&P 500 1,982.45 -4.60 -0.23%
NASDAQ 4,752.7380 -28.5260 -0.60%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs